CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Private Placement	At The Market Offering	Common Stock	Common Stock Private Placement	Common Stock At The Market Offering	Additional Paid in Capital	Additional Paid in Capital Private Placement	Additional Paid in Capital At The Market Offering	Accumulated Other Comprehensive Income / (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023				42,973,215
Beginning balance at Dec. 31, 2023	$ 85,084			$ 43			$ 401,638			$ 3,047	$ (319,644)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock on exercise of stock options (in shares)				303,391
Issuance of common stock on exercise of stock options	225						225
Stock based compensation	2,497						2,497
Foreign currency translation adjustments	(1,955)									(1,955)
Unrealized loss on available for sale investments	(5)									(5)
Net Income (Loss)	(38,878)										(38,878)
Ending balance (in shares) at Jun. 30, 2024				43,276,606
Ending balance at Jun. 30, 2024	46,968			$ 43			404,360			1,087	(358,522)
Beginning balance (in shares) at Mar. 31, 2024				43,215,233
Beginning balance at Mar. 31, 2024	74,177			$ 43			403,102			1,825	(330,793)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share Based Compensation Arrangement by Share based Payment Award Options and Non Option Equity Instruments Exercises in Period				61,373
Issuance of common stock on exercise of stock options and vesting of restricted stock units	35						35
Stock based compensation	1,223						1,223
Foreign currency translation adjustments	(726)									(726)
Unrealized loss on available for sale investments	(12)									(12)
Net Income (Loss)	(27,729)										(27,729)
Ending balance (in shares) at Jun. 30, 2024				43,276,606
Ending balance at Jun. 30, 2024	$ 46,968			$ 43			404,360			1,087	(358,522)
Beginning balance (in shares) at Dec. 31, 2024	44,001,643			44,001,643
Beginning balance at Dec. 31, 2024	$ 30,146			$ 44			406,609			(35)	(376,472)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)					6,671,928	2,766,549
Issuance of common stock	183	$ 746	$ 2,890		$ 6	$ 3	183	$ 740	$ 2,887
Share Based Compensation Arrangement by Share based Payment Award Options and Non Option Equity Instruments Exercises in Period				184,060
Stock based compensation	2,659						2,659
Foreign currency translation adjustments	6,261									6,261
Unrealized loss on available for sale investments	(70)									(70)
Net Income (Loss)	$ (31,079)										(31,079)
Ending balance (in shares) at Jun. 30, 2025	53,624,180			53,624,180
Ending balance at Jun. 30, 2025	$ 11,736			$ 53			413,078			6,156	(407,551)
Beginning balance (in shares) at Mar. 31, 2025				44,089,142
Beginning balance at Mar. 31, 2025	18,581			$ 44			408,082			1,957	(391,502)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)					6,671,928	2,766,549
Issuance of common stock		$ 746	$ 2,890		$ 6	$ 3		$ 740	$ 2,887
Share Based Compensation Arrangement by Share based Payment Award Options and Non Option Equity Instruments Exercises in Period				96,561
Issuance of common stock on exercise of stock options and vesting of restricted stock units	96						96
Stock based compensation	1,273						1,273
Foreign currency translation adjustments	4,216									4,216
Unrealized loss on available for sale investments	(17)									(17)
Net Income (Loss)	$ (16,049)										(16,049)
Ending balance (in shares) at Jun. 30, 2025	53,624,180			53,624,180
Ending balance at Jun. 30, 2025	$ 11,736			$ 53			$ 413,078			$ 6,156	$ (407,551)